In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Reata brings in $17mm so far via its Series G round; adds $61mm

Executive Summary

Reata Pharmaceuticals (developing therapeutics for inflammation) has brought in $17mm so far through its Series G venture round from 30 investors. According to the company's Form D filing, it could bring in a total of $79.3mm. The second tranche of the money is linked to the success of Reata's Phase IIb trial of bardoxolone for diabetics with advanced chronic kidney disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies